OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.otsuka-us.com

Clinical Trials

A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis

Phase 1

Completed

Conditions: Pulmonary TB

Interventions: Drug: 90 mg OPC-167832
Drug: RHEZ
Drug: 10 mg OPC-167832
Drug: 3 mg OPC-167832
Drug: 30 mg OPC-167832
Drug: 30 mg OPC-167832 + 300 mg delamanid + 400 mg BDQ
Drug: 30 mg OPC-167832 + 300 mg delamanid
Drug: 30 mg OPC-167832 + 400 mg BDQ

First Posted Date: 2018-09-20

Last Posted Date: 2023-11-18

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 122

Registration Number: NCT03678688

Locations: 🇿🇦
Satellite Site: Task at Brooklyn Chest Hospital, Cape Town, South Africa
🇿🇦
University of Cape Town (Pty) Ltd., Cape Town, Mowbray, South Africa
🇿🇦
TASK Clinical Research Centre, Cape Town, South Africa

Trial to Evaluate the Long-term Efficacy of Oral Aripiprazole in the Treatment of Pediatric Participants With Tourette's Disorder

Phase 4

Terminated

Conditions: Tourette's Disorder (TD)

Interventions: Drug: Placebo
Drug: Aripiprazole

First Posted Date: 2018-09-07

Last Posted Date: 2021-03-09

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 36

Registration Number: NCT03661983

Locations: 🇺🇸
Reliable Clinical Research, Hialeah, Florida, United States
🇺🇸
Pediatric and Adolescent Neurodevelopment Associates, Atlanta, Georgia, United States
🇺🇸
Alivation, Lincoln, Nebraska, United States

and more 39 locations

A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder

Phase 4

Terminated

Conditions: Schizophrenia
Bipolar 1 Disorder
Major Depressive Disorder

Interventions: Combination Product: Abilify MyCite - Digital Medicine System
Drug: Aripiprazole or other oral antipsychotics

First Posted Date: 2018-08-22

Last Posted Date: 2019-11-08

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 2

Registration Number: NCT03643159

Locations: 🇺🇸
Psychiatric Addiction Curative/PACT Atlanta LLC, Decatur, Georgia, United States
🇺🇸
Kolade Research Institute, Las Vegas, Nevada, United States
🇺🇸
Georgia Psychiatry and Sleep, Smyrna, Georgia, United States

and more 2 locations

A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder

Phase 3

Completed

Conditions: Attention Deficit Disorder
Attention Deficit Hyperactivity Disorder

Interventions: Other: Placebo
Drug: Centanafadine SR

First Posted Date: 2018-07-30

Last Posted Date: 2021-10-18

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 590

Registration Number: NCT03605836

Locations: 🇺🇸
For additional information regarding sites, contact 844-687-8522, Orlando, Florida, United States

A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder

Phase 3

Completed

Conditions: Attention Deficit Disorder
Attention Deficit Hyperactivity Disorder

Interventions: Drug: Centanafadine SR

First Posted Date: 2018-07-30

Last Posted Date: 2024-10-01

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 662

Registration Number: NCT03605849

Locations: 🇺🇸
For additional information regarding sites, contact 844-687-8522, Culver City, California, United States

A Trial Evaluating the Efficacy, Safety, & Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder

Phase 3

Completed

Conditions: Attention Deficit Hyperactivity Disorder
Attention Deficit Disorder

Interventions: Drug: Centanafadine SR
Other: Placebo

First Posted Date: 2018-07-30

Last Posted Date: 2022-03-15

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 604

Registration Number: NCT03605680

Locations: 🇺🇸
For additional information regarding sites, contact 844-687-8522, New York, New York, United States

A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

Phase 3

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Brexpiprazole

First Posted Date: 2018-07-20

Last Posted Date: 2023-11-14

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 259

Registration Number: NCT03594123

Locations: 🇺🇸
For additional information regarding sites, contact 844-687-8522, Miami, Florida, United States

A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic

Phase 4

Completed

Conditions: Schizophrenia
Schizoaffective Disorder
First Episode Psychosis

Interventions: Device: Digital Medicine System
Drug: Aripiprazole
Drug: Olanzapine
Drug: Quetiapine
Drug: Risperidone

First Posted Date: 2018-06-26

Last Posted Date: 2020-07-16

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 44

Registration Number: NCT03568500

Locations: 🇬🇧
Clinical Trial Site, Southampton, United Kingdom

A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type

Phase 3

Completed

Conditions: Agitation Associated With Alzheimer's Dementia
Alzheimer Dementia

Interventions: Drug: Brexpiprazole
Other: Placebo

First Posted Date: 2018-06-07

Last Posted Date: 2023-09-18

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 345

Registration Number: NCT03548584

Locations: 🇺🇸
For additional information regarding sites, contact 844-687-8522, Los Angeles, California, United States

A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder

Phase 3

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Brexpiprazole
Drug: Antidepressant therapy

First Posted Date: 2018-05-29

Last Posted Date: 2023-10-12

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 1149

Registration Number: NCT03538691

Locations: 🇺🇸
For additional information regarding sites, contact 844-687-8522, Los Angeles, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy